Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

24432 ARTÍCULOS , VIENDO DEL 23896 AL 23910

Neuropsychiatric symptoms and neuroimaging-based brain age in mild cognitive impairment and early dementia: A multicenter study

Sone D, Beheshti I, Tagai K, Kameyama H, Takasaki E, Kashibayashi T, Takahashi R, Ishii K, Kanemoto H, Ikeda M, Shigeta M, Shinagawa S, Kazui H.

Psychiatry Clin Neurosci. 2025 Apr;79(4):158-164. doi: 10.1111/pcn.13777. Epub 2025 Jan 17.

Zinc Therapy in Mild Cognitive Impairment: Cognitive Stabilization in Pharmacodynamically Responsive Patients in the ZINCAiD Trial

Squitti R, Benussi A, Fostinelli S, Geviti A, Rivolta J, Ventriglia M, Micera A, Rongioletti M, Ghidoni R, Santilli M, Granzotto A, Albanese A, Binetti G, Sensi SL, Borroni B.

Biomolecules. 2025 Sep 1;15(9):1268. doi: 10.3390/biom15091268.

Effectiveness of Individual Cognitive Stimulation on Cognition in Mild Alzheimer's Disease: A Multicenter RCT

Justo-Henriques SI, Lemos R, Rahmatpour P, Silva RCG, Carvalho JO, Ribeiro O.

Psychogeriatrics. 2025 Nov;25(6):e70109. doi: 10.1111/psyg.70109.

Total and Structural Carotid Artery Stiffness Are Associated With Cognitive Decline and Structural Brain Abnormalities Related to Alzheimer Disease and Alzheimer Disease-Related Dementias Pathology: The Multi-Ethnic Study of Atherosclerosis

Williams JR, DeConne TM, Pewowaruk R, Korcarz C, Tanley J, Carlsson C, Heckbert SR, Habes M, Nasrallah I, Lockhart SN, Luchsinger JA, Ding J, Hayden KM, Hughes TM, Gepner AD.

J Am Heart Assoc. 2025 May 6;14(9):e039925. doi: 10.1161/JAHA.124.039925. Epub 2025 May 2.

A mobile interactive cognitive self-assessment scale for screening cognitive impairment due to Alzheimer's disease

Xie K, Huang J, Chen T, Li D, Xia T, Chu M, Cui Y, Tang M, Peng D, Wang J, Liu J, Chen X, Cui W, Liu L, Wang Y, Liu J, Li F, Wu L.

Age Ageing. 2025 Jan 6;54(1):afae293. doi: 10.1093/ageing/afae293.

High definition transcranial direct current stimulation as an intervention for cognitive deficits in Alzheimer's dementia: A randomized controlled trial

LoBue C, Chiang HS, Salter A, McClintock S, Nguyen TP, Logan R, Smernoff E, Pandya S, Hart J.

J Prev Alzheimers Dis. 2025 Feb;12(2):100023. doi: 10.1016/j.tjpad.2024.100023. Epub 2025 Jan 1.

Tablet-based Cognitive Assessment Tool (TabCAT) in a multisite study of early-onset Alzheimer's disease

Njamnshi WY, Chiotis K, Tsoy E, Blazhenets G, Maiti P, Zhang J, Allen IE, Rocha S, Shankar RP, Amuiri A, Lawson M, Aisen P, Beckett L, Eloyan A, Hammers DB, Kirby K, Koeppe R, Kukull WA, Toga AW, Atri A, Clark D, Day GS, Duara R, Graff-Radford NR, Grant I, Honig LS, Johnson ECB, Jones DT, Masdeu J, Mendez MF, Musiek E, Onyike CU, Riddle M, Rogalski E, Salloway S, Sha SJ, Turner RS, Wingo TS, Wolk DA, Womack K, Kramer JH, Touroutoglou A, Brickhouse MJ, Jack CR Jr, Vemuri P, Taurone A, Thangarajah M, Nudelman K, Carrillo MC, Dickerson BC, Apostolova LG, Possin KL, Rabinovici GD, La Joie R; LEADS Consortium.

Alzheimers Dement. 2025 Dec;21(12):e71012. doi: 10.1002/alz.71012.

Independent validation and outlier analysis of EuroPOND alzheimer's disease staging model using ADNI and real-world clinical data

Wittens MMJ, Sima DM, Brys A, Struyfs H, Niemantsverdriet E, De Roeck E, Bastin C, Benoit F, Bergmans B, Bier JC, de Deyn PP, Deryck O, Hanseeuw B, Ivanoiu A, Picard G, Salmon E, Segers K, Sieben A, Thiery E, Tournoy J, van Binst AM, Versijpt J, Smeets D, Bjerke M, Bellio M, Oxtoby NP, Alexander DC, Ribbens A, Engelborghs S.

Alzheimers Res Ther. 2025 Jun 16;17(1):134. doi: 10.1186/s13195-025-01788-6.

A meta-analysis and systematic review of interventions to prevent or treat cognitive decline related to Alzheimer's disease in adults with Down syndrome

Munn EE, Montelongo A, Patel VK, Fodstad JC, Ciccarelli MR, Ptomey LT, Pangelinan MM.

Alzheimers Dement. 2025 Jul;21(7):e70471. doi: 10.1002/alz.70471.

The effect of tablet-based multimodal training on cognitive functioning in Alzheimer's disease: A randomized controlled trial

Zuschnegg J, Ropele S, Opriessnig P, Schmidt R, Russegger S, Fellner M, Leitner M, Spat S, Garcia ML, Strobl B, Ploder K, Pszeida M, Hofmarcher-Holzhacker MM, Stoegerer-Oberschmid E, Guttmann-Lattmanig A, Paletta L, Schüssler S, Koini M.

PLoS One. 2025 Aug 13;20(8):e0329931. doi: 10.1371/journal.pone.0329931. eCollection 2025.

Protocol for a Randomized Phase II/III Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Extended-Release Metformin in Amnestic Mild Cognitive Impairment: Metformin in Alzheimer Dementia Prevention (MAP)

Luchsinger JA, Devanand D, Goldberg TE, Cammack S, Hernández-Santiago G, Oishi K, Jagust W, Baker S, Landau S, Yenokyan G, Betz J, Mayers S, Eyzaguirre LM, Hanley D; MAP Study Group.

Alzheimer Dis Assoc Disord. 2025 Apr-Jun 01;39(2):123-133. doi: 10.1097/WAD.0000000000000677. Epub 2025 May 28.

Sativex (nabiximols) for the treatment of Agitation & Aggression in Alzheimer's dementia in UK nursing homes: a randomised, double-blind, placebo-controlled feasibility trial

Albertyn CP, Guu TW, Chu P, Creese B, Young A, Velayudhan L, Bhattacharyya S, Jafari H, Kaur S, Kandangwa P, Carter B, Aarsland D.

Age Ageing. 2025 May 31;54(6):afaf149. doi: 10.1093/ageing/afaf149.

Functional Imaging in Alzheimer's Disease: A Systematic Review and Meta-Analysis of ASL-MRI and FDG-PET

Radmard M, Gad M, Sheikhy A, Dagher R, Yedavalli V, Luna LP.

J Neuroimaging. 2025 Sep-Oct;35(5):e70080. doi: 10.1111/jon.70080.

Brexpiprazole for agitation in clinically relevant patient subgroups: a post hoc analysis of efficacy and safety in patients with agitation associated with dementia due to Alzheimer's disease

Stroud J, Cummings JL, Chumki SR, Such P, Wang D, Palma AM, Zhang Z, Brubaker M, Grossberg GT.

Curr Med Res Opin. 2025 Aug;41(8):1523-1534. doi: 10.1080/03007995.2025.2552278. Epub 2025 Sep 5.

Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer's Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled, 78-Week APOLLOE4 Trial

Abushakra S, Power A, Watson D, Porsteinsson A, Sabbagh M, MacSweeney E, Cohen S, Boada Rovira M, Doraiswamy PM, Liang E, Flint S, Kesslak JP, McLaine R, Albayrak A, Schaefer J, Yu J, Tolar L, Dickson S, Hey JA, Tolar M.

Drugs. 2025 Nov;85(11):1455-1472. doi: 10.1007/s40265-025-02250-5. Epub 2025 Sep 28.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias